AI Data Protection in Biotech Depends on Part 11 Scope and System Control

A scientist stands at a lab bench with a barcode scanner in one hand and a tablet in the other. A failed-assay record is open, and an approved assistant is ready to draft the deviation description. The request may carry a sample identifier, instrument output and a regulated record excerpt to an external model. AI data protection biotech controls have to decide who may send that content and where before the HTTP request leaves.

Part 11 provides a useful control frame only after scope is established. A biotech logo on the tablet does not make every prompt a Part 11 record.

TL;DR

• Part 11 follows electronic records required by FDA predicate rules and specified electronic submissions, rather than every biotech document.
• Closed systems require authorized access, record protection, authority checks and other controls that can reach an LLM request carrying an in-scope record.
• Open systems require additional measures, such as encryption and appropriate digital-signature standards, as necessary under the circumstances.
• HTTP enforcement cannot validate the model, determine GxP scope, govern local inference or replace quality review and change control.

Part 11 scope follows the regulated record

The Part 11 scope provision covers electronic records maintained under FDA record requirements and specified electronic submissions. It reaches creation, modification, storage, retrieval and transmission when those activities concern an in-scope record.

That language keeps the analysis tied to the predicate rule and record purpose. A model request that rewrites a lunch menu for the research cafeteria sits outside this frame. A request that summarizes stability results for a record required under an applicable FDA rule may sit inside it. Quality and regulatory owners make that determination.

The enforcement layer should receive the result as record context rather than attempt to infer GxP status from scientific vocabulary. I think blocking an unclassified external request is more defensible than asking a content scanner to decide which FDA rule governs a paragraph. AI vendor risk in biotech covers the provider assessment that accompanies that route decision.

System control determines the protection pattern

The Part 11 definitions distinguish a closed system, where access is controlled by people responsible for the records' content, from an open system, where those people lack that access control.

Internet connectivity alone does not settle the classification. A hosted application can still use tightly administered identities and access paths. An internal system with poorly controlled external accounts can present a different answer. Document who controls access to the record, model route and destination tenant.

For managed LLM traffic, the practical design starts with an authenticated human or workload, an approved application and a provider tenant governed by policy. Shared keys weaken attribution and make role checks harder. Give the calling service its own identity, preserve the initiating person's context where available and restrict the endpoint to the models approved for that use.

Closed-system controls reach the request boundary

The Part 11 closed-system controls require measures that help assure authenticity, integrity and, when appropriate, confidentiality. They include limiting access to authorized individuals, authority checks, source or device checks where appropriate, record protection and system validation.

At the LLM boundary, access control asks if the authenticated scientist or service may use the approved application. An authority check asks if that identity may perform this operation on this record class. Destination policy decides which provider and model may receive the content. A source check can restrict traffic to the validated application route rather than a personal browser session.

Those controls should act before transmission. A later alert can support response, but it arrives after the regulated content has reached the model. Policy enforcement at the HTTP layer describes the inline decision point without claiming that the proxy validates the surrounding GxP system.

Open-system protection needs more than a lock icon

The Part 11 open-system requirements call for the applicable closed-system controls plus additional measures, such as document encryption and appropriate digital-signature standards, as necessary to protect authenticity, integrity and confidentiality through creation and receipt.

For an external LLM route, TLS is the starting point. It protects content moving between the enterprise control point and provider endpoint. It does not establish that the scientist had authority for the operation, that the selected tenant was approved, that the provider preserved record integrity or that the output belongs in a regulated record.

Avoid turning the "such as" language into a claim that every API request requires a digital signature. The required measures depend on the circumstances and documented system design. The organization still needs a reasoned decision covering encryption, identity, integrity and receipt.

Data minimization protects both prompt and control record

A deviation assistant rarely needs an entire batch record. Give it the fields required for the approved task, remove unrelated personal or proprietary content, and bind the route to the model assessed for that purpose. The request policy can block excluded identifiers or require redaction before forwarding.

The control event needs restraint too. Full prompts and responses may contain batch details, formulas, patient-adjacent information or investigation findings. Sending every payload to a general observability store creates another repository outside the quality system.

Keep identity, application, record class, destination, time and policy result in the event. Use a protected record reference or hash when the full content stays in a system with tighter access. Biotech AI audit trails examines Part 11 evidence and retention in depth; data protection design should avoid duplicating that record without a defined purpose.

Provider change control remains a quality responsibility

A route can pin an approved provider and model identifier, then block an unapproved version until the accountable team approves it.

The proxy cannot demonstrate that a model performs consistently for its intended use; it cannot write the validation protocol, assess scientific accuracy, approve a deviation or determine the governing retention rule, as those remain quality-system functions under Part 11 and the applicable FDA requirements.

Model terms and hosting choices still need supplier review. Route policy applies that decision without replacing diligence on retention, administrative access and incident handling.

The HTTP boundary has defined exclusions

An inline gateway can inspect authenticated HTTP traffic between scientists or agents and LLM endpoints. It can validate supplied identity, classify content, enforce approved routes, redact selected fields and stop a request before transmission.

A local model running on a laboratory workstation falls outside that path. So does inference performed entirely inside a laboratory information management system vendor's environment, a file copied through removable storage or instrument traffic that never calls an LLM endpoint. Endpoint, vendor and laboratory controls cover those cases.

Scope claims should name the routed applications and endpoint population tested in October 2026. "All AI used by research is covered" is too broad when one instrument vendor has embedded its own model. Precise exclusions make the control credible and tell quality assurance where to request separate evidence.

DeepInspect

DeepInspect is a stateless proxy for authenticated HTTP traffic between biotech users or agents and LLM endpoints. It evaluates application-supplied identity, record classification, approved destination and policy before forwarding. Each permit, redaction, reroute or block creates a signed per-decision record outside the calling application's write path.

For managed routes, DeepInspect can restrict regulated content to an approved provider and model, enforce authority supplied by the application and stop excluded data before transmission. It does not determine Part 11 scope, validate the LLM or quality system, govern local inference, control vendor-native models or make scientific and GxP judgments.

Book a demo today.